Behind the Podium: Best Practices for Making It into the Conference Circuit
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. George Han, associate professor of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Watch as Dr. Han shares his tips for breaking into the conference circuit. Learn why it’s important to find your niche and the right mentor. Hear which meeting Dr. H …
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. George Han, associate professor of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Watch as Dr. Han shares his tips for breaking into the conference circuit. Learn why it’s important to find your niche and the right mentor. Hear which meeting Dr. H … Continue reading "Behind the Podium: Best Practices for Making It into the Conference Circuit"
These lesions can occur with which of the following?
A. Morphea
B. Leprosy
C. Erythema nodosum
D. Sarcoid
E. Pregnancy
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
… 
Increased expression of which of the following is most associated with the patient’s condition?
A. Interferon-gamma
B. Interleukin-2
C. Interleukin-13
D. Transforming growth factor-beta
E. Tumor necrosis factor-alpha
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
… 
At ODAC 2023, we had the opportunity to learn about cicatricial alopecias from renowned dermatologist and hair expert Dr. Amy McMichael, Professor of Dermatology at Wake Forest University School of Medicine.
First, we considered a framework to check for cicatricial alopecias. This is particularly important because if we can identify cicatricial alopecia, we can make sure we are treating the rig … 
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT …